Skip to content

Caudal Dexmedetomidine vs Ketamine for Postoperative Analgesia in Pediatric DDH Surgery

Comparative Evaluation of Caudal Dexmedetomidine and Caudal Ketamine as Adjuvants to Isobaric Bupivacaine for Postoperative Analgesia in Children Undergoing Surgery for Developmental Dysplasia of the Hip

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07385352
Acronym
CDK-DDH
Enrollment
54
Registered
2026-02-04
Start date
2026-03-01
Completion date
2026-09-01
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Developmental Dysplasia of the Hip

Keywords

Caudal block Dexmedetomidine Ketamine Pediatric analgesia Bupivacaine Postoperative pain Hip surgery DDH

Brief summary

This study compares two medicines, Dexmedetomidine and Ketamine, added to caudal Bupivacaine to control pain after hip surgery in children. We will check how well each medicine reduces pain, how long the pain relief lasts, and if children need extra pain medicine. The goal is to find the safest and most effective option for postoperative pain relief in children undergoing hip surgery.

Detailed description

Background: Postoperative pain control is a major concern in pediatric patients undergoing surgery for developmental dysplasia of the hip (DDH). Caudal epidural block with Isobaric Bupivacaine is a common technique, but its duration of analgesia is limited. Adjuvants such as Dexmedetomidine and Ketamine may prolong analgesia and improve postoperative comfort. Objective: To compare the efficacy and safety of caudal Dexmedetomidine versus caudal Ketamine as adjuvants to Isobaric Bupivacaine for postoperative analgesia in children undergoing DDH surgery. Study Design: Randomized, double-blind, parallel-group clinical trial Participants: Pediatric patients scheduled for DDH corrective surgery Interventions: Group A: Caudal Bupivacaine + Dexmedetomidine Group B: Caudal Bupivacaine + Ketamine Outcomes: Primary: Postoperative pain scores using FLACC scale Secondary: Duration of analgesia, need for rescue analgesia, hemodynamic stability, and adverse effects Significance: This study aims to provide evidence for the most effective and safe adjuvant for pediatric caudal analgesia, reducing opioid use and improving postoperative comfort and recovery in children undergoing hip surgery.

Interventions

DRUGDexmedetomidine

Dexmedetomidine 1 µg/kg added to caudal Bupivacaine.

DRUGKetamine

Ketamine 0.5 mg/kg added to caudal Bupivacaine.

DRUGBupivacaine

Isobaric Bupivacaine 0.25% 1 ml/kg used for caudal block in both groups.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Double-blind study: neither the patient, the anesthesiologist administering the block, nor the assessor recording pain scores will be aware of group allocation.

Intervention model description

Children are randomized to receive either Dexmedetomidine or Ketamine as adjuvant to caudal Bupivacaine for postoperative analgesia following developmental dysplasia of the hip (DDH) surgery.

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 1 to 6 years undergoing surgery for developmental dysplasia of the hip * ASA physical status I or II * Parental or guardian informed consent obtained

Exclusion criteria

* Known allergy to local anesthetics, Dexmedetomidine, or Ketamine * Coagulopathy or bleeding disorders * Infection at the site of caudal injection * Neurological disorders * Severe systemic disease * Refusal of parental consent

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Pain Score (FLACC)First 24 hours post-surgeryPain will be assessed using the FLACC scale (Face, Legs, Activity, Cry, Consolability) at regular intervals (every 2-4 hours) during the first 24 hours after surgery to evaluate the effectiveness of caudal analgesia in children receiving Dexmedetomidine or Ketamine as adjuvants to Bupivacaine.

Secondary

MeasureTime frameDescription
Hemodynamic StabilityIntraoperative and first 24 hours post-surgeryMonitoring blood pressure and heart rate intraoperatively and postoperatively to assess safety of caudal adjuvants.
Duration of AnalgesiaFrom caudal block to first request for rescue analgesiaTime from caudal block administration to first request for rescue analgesia, measured in hours, to compare the prolongation of analgesia between Dexmedetomidine and Ketamine groups.
Adverse EffectsFirst 24 hours post-surgeryRecording any side effects related to caudal adjuvants, including bradycardia, hypotension, nausea, vomiting, and sedation, during the first 24 hours.
Rescue Analgesia RequirementFirst 24 hours post-surgeryNumber of patients requiring additional analgesia within the first 24 hours post-surgery.

Countries

Egypt

Contacts

CONTACTAbdelmon
Esraa.17289861@med.aun.edu.eg+201116251563
PRINCIPAL_INVESTIGATOREsraa Abdelmonem, MSc

Assiut University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026